Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Abstract Background Previous studies have demonstrated that left-sided tumors have better prognoses than right-sided tumors in RAS wild-type mCRC (metastatic colorectal cancer) patients, while anti-EGFR mAbs appear to have no advantage compared with bevacizumab for right-sided tumors in these patien...

Full description

Bibliographic Details
Main Authors: Datian Chen, Xiang Zhang, Guangyi Gao, Lili Shen, Jiaqi Xie, Xiaoping Qian, Huiyu Wang
Format: Article
Language:English
Published: BMC 2018-10-01
Series:World Journal of Surgical Oncology
Subjects:
Metastatic colorectal cancer
Primary tumor location
Anti-EGFR mAb
Resection
Conversion therapy
Online Access:http://link.springer.com/article/10.1186/s12957-018-1502-7

Internet

http://link.springer.com/article/10.1186/s12957-018-1502-7

Similar Items